A comparative study of the effects of risperidone and olanzapine on metabolic parameters of schizophrenic patients

Sanjay B. Nanotkar, Balwant K. Choure, Devesh D. Gosavi


Background: Risperidone and olanzapine are the most commonly prescribed antipsychotic drugs. There is an overwhelming need to look into the adverse effects induced by these drugs; metabolic disturbance being one of the important of them. Metabolic disturbance induced by these drugs is a little searched domain; Most of the literature on their metabolic adverse effects is based on retrospective analysis. Moreover there is a distinct lack of information on the metabolic adverse effects of these drugs in Indian subjects with special reference to rural population.

Methods: The present study was a prospective, open label, observational study conducted on 189 consecutive new subjects who were prescribed either risperidone (n=93) and olanzapine (n=96) in the psychiatry department of a rural medical college and hospital.

Results: Patients on treatment of risperidone (n=84) showed an increase in all the variables except for HDL cholesterol levels which showed fall. The increases in weight, body mass index were found to be extremely significant (p<0.001). While the rise in the systolic and diastolic blood pressure, fasting sugars and triglycerides, changes was not significant. The fall in HDL cholesterol was not statistically significant.

Conclusions: We conclude from this study that both risperidone and olanzapine have propensity to produce metabolic syndrome in subjects who use them. When compared, olanzapine has a higher chance to produce metabolic syndrome in subjects who were prescribed it, as compared to subjects who were on risperidone.


Risperidone, Olanzapine, Metabolic, Parameters, BMI, Metabolic syndrome

Full Text:



Bhanji NH, Tempier R, Bhanji NH TR. Managing schizophrenia during the stable phase: Is there consensus among practice guidelines? Can J psychiatry. 2002;47(1):47.

Wahlbeck K, Tuunainen A, Ahokas ALS. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology. 2001;155:230-3.

Glick IBP. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. International clinical psychopharmacology. 2002;17:65-8.

Davis JM, Chen NGI, Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-64.

Conley RR. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158:765-74.

Marder SR, Davis JM CG, Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-46.

Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-65.

Aronson JK. Risk perception in drug therapy. 2006;135-7.

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-96.

Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44(8):778-83.

Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5):425-33.

Cooper C, Bebbington P, King M, Brugha T, Meltzer H, Bhugra D, et al. Why people do not take their psychotropic drugs as prescribed: results of the 2000 national psychiatric morbidity survey. Acta Psychiatr Scand. 2007;116(1):47-53.

Lingeswaran A, Harshashetty, Kigshuklohan, Amitparamel SG. A letter to the editor. Ind J Ppharmacol. 2010;42.

Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry. 2001;62(2):5-12.

Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70(1):1-17.

Ingole S, Belorkar NR, Waradkar P, Shrivastava M. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients. Indian J Physiol Pharmacol. 2009;53(1):47-54.

Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(1):1-93.

Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry. 2004;65(5):686-9.

Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27-35.

Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry. 2006;51(8):502-11.

Garyfallos G, Dimelis D, Kouniakis P, Sidiropoulos N, Karastergiou A, Lavrentiadis G, et al. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. Eur Psychiatry. 2003;18(6):320-1.

Ganguli R, Brar JS, Ayrton Z. Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophr Res. 2001;49(3):261-7.

Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, et al. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry. 2004;65(4):547-50.

Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999;60(11):767-70.

Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry. 1999;156(9):1471-2.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007;164(3):415-27.

Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT, et al. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry. 2001;34(6):223-31.

Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry. 2011;53(2):128-33.

Kinon BJ, Liu-Seifert H, Ahl J, Ahmed S, Baker RW. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study. Ann N Y Acad Sci. 2004;1032:295-6.

Krane-Gartiser K, Breum L, Glumrr C, Linneberg A, Madsen M, Koster A, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry. 2011;65(5):345-52.

Cerit C, Vural M, Bos Gelmez SU, Ozten E, Aker AT, Yildiz M. Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study. Psychopharmacol Bull. 2010;43(4):22-36.